Ultragenyx Pharmaceutical Sees Interim Q3 FY23 Sales Of $96M-$100M Versus Consensus Of $113.33M; Cash, Cash Equivalents, And Marketable Debt Securities Of Approximately $525M
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical has projected its interim Q3 FY23 sales to be between $96M-$100M, which is lower than the consensus estimate of $113.33M. The company also reported cash, cash equivalents, and marketable debt securities of approximately $525M.
October 16, 2023 | 12:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ultragenyx Pharmaceutical's lower than expected Q3 FY23 sales projection could negatively impact its stock price.
Ultragenyx Pharmaceutical's projected sales for Q3 FY23 are lower than the consensus estimate. This could lead to a negative sentiment among investors, potentially driving the stock price down in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100